Kisspeptin
The master switch for the human reproductive hormone system — and, perhaps surprisingly, one of the compounds on this site with the most substantial real human trial record, despite never becoming an approved medicine.
Kisspeptin (KISS1-derived peptides, e.g. kisspeptin-54)
Naturally occurring neuropeptide, synthetic forms used in research
Reproductive endocrinology · fertility · sexual/emotional brain processing
Yes — multiple published RCTs, including fMRI studies
Investigational — no approval identified in the UK, EU, or US for any use
5 October 2026
Kisspeptin isn't a single synthetic invention — it's a family of peptides the human body produces naturally, encoded by the KISS1 gene. Kisspeptin-54 is the longer, full-length circulating form most often used in clinical research because of its longer half-life. Unlike most compounds on this site, kisspeptin research starts from a well-established normal physiological role, not a hypothesis about a synthetic molecule.
Kisspeptin sits right at the top of the hypothalamic-pituitary-gonadal (HPG) axis — the system that governs puberty, fertility, and reproductive hormone levels in both sexes. Mice lacking the kisspeptin receptor fail to enter puberty at all, which is about as strong a signal of biological importance as preclinical research gets. That central role has made it a genuine research target for fertility treatment, diagnosing reproductive hormone disorders, and — more recently — sexual desire and arousal, since the same signalling system appears to influence brain regions involved in sexual and emotional processing.
Well-established
Kisspeptin binds its receptor (KISS1R/GPR54) on GnRH-secreting neurons, triggering GnRH release and, downstream, the pulsatile release of luteinising hormone (LH) that drives the reproductive axis. This pathway is one of the better-characterised neuroendocrine systems in human biology.
Still being worked out
Kisspeptin's direct effects on brain regions involved in sexual and emotional processing — separate from its hormonal effects via the HPG axis — are a newer, actively studied research area, not yet as fully mapped as the core GnRH-stimulating pathway.
Laboratory / Animal
Extensive preclinical work establishing the KISS1/KISS1R-GnRH pathway, including knockout-mouse puberty studies.
Early & Controlled Human Research
Multiple published randomized clinical trials: oocyte maturation in IVF (175 participants), hormone/reproductive studies, and fMRI-based RCTs on sexual brain processing in both men and women with hypoactive sexual desire disorder.
Diagnostic clinical use
Used in hospital-based diagnostic evaluation of the HPG axis, e.g. distinguishing transient delayed puberty from permanent hypogonadotropic hypogonadism.
Established Clinical Evidence / Approval
None identified — despite the research volume, kisspeptin has not been developed into an approved medicine for any of these uses.
- Population/model
- Women undergoing IVF (175 participants across the related trial programme)
- Design
- Clinical trial, kisspeptin-54 used to trigger oocyte maturation
- What researchers found
- Successful egg maturation, fertilization, and embryo transfer; pregnancies resulted
- Major limitation
- Specific to the IVF-trigger context — doesn't establish broader fertility or sexual-health claims
- Population/model
- 32 premenopausal women with HSDD
- Design
- Randomized, placebo-controlled; 75-minute IV kisspeptin-54 infusion vs. placebo
- What researchers found
- Modulated sexual/attraction brain processing on fMRI; correlated with psychometric measures of sexual aversion and distress; well-tolerated, no reported adverse effects
- Major limitation
- Small trial; single-dose infusion design, not a real-world repeated-use protocol
- Population/model
- 37 randomized, 32 completed — men with HSDD
- Design
- Double-blind, 2-way crossover, placebo-controlled RCT
- What researchers found
- Increased penile tumescence (up to 56% above placebo) in response to sexual stimuli; modulated brain activity in sexual-processing regions
- Major limitation
- Small, short-term study; crossover design has its own statistical trade-offs
Our Clinical Trials Tracker currently lists two registered Imperial College London kisspeptin trials (the IVF study, NCT01667406, and a sustained-administration study, NCT02081924). The HSDD studies cited above are separately published, peer-reviewed RCTs — we have not yet confirmed a specific registry entry for each on the Tracker, which is a gap worth closing in a future update rather than something this article can resolve on its own. [VERIFICATION REQUIRED — registry IDs for the HSDD trials]
"Kisspeptin is a proven treatment for low libido and fertility problems."
Multiple small-to-moderate, peer-reviewed, placebo-controlled human RCTs showing real effects on brain processing, arousal measures, and successful use as an IVF trigger agent.
That kisspeptin administration produces measurable, real effects in these specific, controlled research contexts. It does not support "proven treatment" framing — none of this research has led to an approved medicine, and the trials are small, short-term studies, not large-scale confirmatory Phase 3 programmes.
Whether these effects hold up in larger, longer trials; the right dose and administration route for any eventual therapeutic use; and why, despite a genuinely strong research signal, no company has carried kisspeptin through to an approved product.
Small human studiesThe HSDD trials involve around 30 participants each — real signal, but a small base to generalise from.
Short follow-up / single-dose designsSeveral key trials use single infusions, not sustained real-world dosing regimens.
Surrogate outcomesBrain-imaging and tumescence measures are meaningful research endpoints, not the same as long-term clinical outcome data.
No approved product despite the research baseWorth noting as a genuine open question, not explained away.
No regulatory approval for kisspeptin has been identified in the UK, EU, or US for any indication — it remains an investigational research compound, including in its diagnostic hospital use, which operates in a specialist clinical research context rather than as a licensed product. Read the full UK regulatory framework →
What We Still Don't Know
- Whether the sexual-brain-processing effects seen in small trials hold up in larger, longer studies.
- What a real-world, repeated-dose regimen would look like, and whether its effects or safety profile would differ from the single-infusion studies.
- Why, despite a genuinely substantial and positive human research base, kisspeptin hasn't been carried through to an approved medicine by any manufacturer.
Jayasena CN, et al., J Clin Invest, 2014 (DOI 10.1172/JCI75730). Thurston L, et al., JAMA Network Open, 2022 (DOI 10.1001/jamanetworkopen.2022.36131). Mills EG, et al., JAMA Network Open, 2023 (DOI 10.1001/jamanetworkopen.2022.54313). ClinicalTrials.gov records NCT01667406 and NCT02081924, verified via the official registry API. General KISS1/KISS1R-GnRH pathway mechanism as described in peer-reviewed endocrinology review literature (ScienceDirect, PMC-indexed sources).